The Influence of the MDR1 C3435T Polymorphism on Methotrexate Responsiveness in Rheumatoid Arthritis Patients
July 2020
in “
The Egyptian Journal of Hospital Medicine
”
TLDR The MDR1 C3435T polymorphism does not significantly affect methotrexate response in rheumatoid arthritis patients.
This study investigated the influence of the MDR1 C3435T polymorphism on methotrexate responsiveness in 90 rheumatoid arthritis patients, predominantly female (88.9%). Patients were categorized into methotrexate responders and non-responders based on their disease activity score (DAS28). The study found no statistically significant difference in genotype or allele frequencies between the two groups. However, patients with the C allele were 1.65 times more likely to be non-responders compared to those with the T allele. Common methotrexate adverse effects included gastrointestinal upset (31.1%) and hair loss (11.1%). The study concluded that there was no significant association between the MDR1 C3435T polymorphism and methotrexate responsiveness in these patients.